Renafor-G Inhaler is a dual-action bronchodilator inhaler that combines Glycopyrronium Bromide and Formoterol Fumarate for the management of chronic obstructive pulmonary disease (COPD) and other persistent obstructive airway conditions. This combination provides both long-acting muscarinic antagonism and beta-2 adrenergic agonist activity, offering effective and sustained bronchodilation to improve airflow and ease breathing.

• Glycopyrronium Bromide is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine receptors in the airways, preventing bronchoconstriction and keeping the airways open.

• Formoterol Fumarate is a long-acting beta-2 agonist (LABA) that relaxes airway smooth muscles, enhancing airflow and reducing symptoms such as wheezing, breathlessness, and chronic cough.

By combining these two bronchodilators in a single inhaler, Renafor-G provides rapid and sustained relief of airway obstruction, reduces the risk of exacerbations, and improves overall lung function in patients with COPD.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each puff of Renafor-G Inhaler contains:

• Glycopyrronium Bromide – 9 mcg

• Formoterol Fumarate – 4.8 mcg

Mechanism of Action

Renafor-G works through the complementary actions of its components:

• Glycopyrronium Bromide (LAMA): Blocks muscarinic receptors in the airways, reducing bronchial constriction and maintaining airway patency.

• Formoterol Fumarate (LABA): Stimulates beta-2 adrenergic receptors, causing smooth muscle relaxation and bronchodilation.

Together, these mechanisms provide long-lasting bronchodilation, improve airflow, and reduce symptoms of chronic airway obstruction.

Indications

Renafor-G Inhaler is indicated for:

• Maintenance therapy of chronic obstructive pulmonary disease (COPD)

• Management of moderate to severe persistent airway obstruction

• Reduction of COPD exacerbations and improvement of breathing function

• Patients requiring dual bronchodilator therapy for long-term respiratory control

It is not intended for acute relief of sudden shortness of breath; a short-acting rescue inhaler should be used for immediate symptom control.

Dosage and Administration

The dosage should be individualized according to patient condition:

• Typical dose: 1–2 puffs twice daily, or as prescribed by a physician

• Shake the inhaler well before use

• Exhale completely, place the mouthpiece in the mouth, and inhale deeply while pressing the canister

• Hold your breath for 5–10 seconds, then exhale slowly

• Rinse the mouth after use if necessary

Consistent use as prescribed is essential for optimal management of COPD symptoms.

Possible Side Effects

Common side effects may include:

• Dry mouth

• Cough or throat irritation

• Tremors or palpitations

• Headache

Rare but serious side effects may include:

• Allergic reactions

• Severe cardiovascular effects

• Worsening of respiratory symptoms

Patients should contact their healthcare provider if severe or persistent symptoms occur.

Precautions and Warnings

• Inform your doctor about heart disease, high blood pressure, or arrhythmias

• Not for use as a rescue inhaler

• Use caution in patients with kidney or liver impairment

• Regular monitoring of lung function may be required

Use in Pregnancy and Lactation

Renafor-G Inhaler should only be used during pregnancy or breastfeeding if clearly necessary and prescribed by a physician. Benefits and risks must be carefully evaluated.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage

• Store below 30°C in a dry place

• Keep inhaler upright and protected from direct sunlight

• Keep out of reach of children

Conclusion

Renafor-G Inhaler (Glycopyrronium Bromide + Formoterol Fumarate) is a dual bronchodilator therapy for the long-term management of COPD. By combining muscarinic antagonism with beta-2 agonist activity, it provides sustained bronchodilation, improved airflow, and reduced exacerbations, enhancing quality of life in patients with chronic respiratory conditions.